Daré Bioscience and Rosy Wellness Partner to Promote DARE to PLAY Sildenafil Cream

Daré Bioscience, Inc., a biopharmaceutical firm focused on innovating women's health solutions, has forged a strategic alliance with Rosy Wellness, a digital platform dedicated to supporting women's health. The collaboration aims to bolster the marketing and awareness campaign for Daré's new product, DARE to PLAY Sildenafil Cream. This topical cream, containing sildenafil citrate—the active ingredient in Viagra—is designed to enhance blood flow to genital tissues, aiding women's sexual arousal. Daré plans to offer it by prescription in the United States by the fourth quarter of 2025, under Section 503B of the Federal Food, Drug, and Cosmetic Act.

The partnership combines Daré's clinical expertise in women's health with Rosy Wellness' extensive digital outreach and community engagement. Rosy Wellness boasts a wide-reaching community of over 250,000 women, with 65% of respondents to its Female Sexual Function Index questionnaire highlighting concerns about sexual arousal. The collaboration seeks to educate consumers and healthcare providers, encouraging open discussions on female sexual wellness and promoting the DARE to PLAY Sildenafil Cream, which aims to help women regain intimacy and satisfaction.

Sabrina Martucci Johnson, President and CEO of Daré Bioscience, emphasized the importance of addressing underserved female sexual health needs. She noted that partnering with Rosy Wellness opens doors to connect with women authentically, fostering open discussions about sexual wellness. Rosy Wellness, led by Founder and CEO Lyndsey Harper, MD, is committed to bridging gaps in women's healthcare. By providing evidence-based solutions and accessible resources, Rosy aims to draw attention to sexual wellness—a historically overlooked area—and expand educational and support services.

Rosy Wellness is dedicated to empowering women with resources and community support, starting with sexual health and extending across the spectrum of women's health. Founded by board-certified OB-GYN Lyndsey Harper, Rosy addresses neglected aspects of women's care through a digital platform offering personalized education, self-guided tools, community interaction, and health coaching. Rosy aims to redefine how women manage their health, providing judgment-free, medically backed support for issues like sexual dysfunction, menopause, migraines, and emotional well-being.

Daré Bioscience, meanwhile, continues its mission to challenge the status quo in women's health, focusing on delivering innovative solutions to unmet needs in areas such as contraception, sexual health, pelvic pain, fertility, infectious diseases, vaginal health, and menopause. Daré leverages existing clinical data and safety information to bring products to market efficiently, ensuring optimal access for women. Their portfolio includes the FDA-approved XACIATO™ for bacterial vaginosis, Ovaprene®—a hormone-free contraceptive—and DARE-HRT1, an intravaginal ring for menopausal hormone therapy.

The partnership with Rosy Wellness highlights a shared commitment to advancing sexual health equity and ensuring women have access to the necessary information and solutions. Both companies aim to destigmatize discussions around female sexual health and provide comprehensive support to enhance women's health and well-being.